// App-Quantinova.ai

: Cost-effectiveness of single-inhaler triple therapy for chronic obstructive pulmonary disease treatment by baseline blood eosinophil count: IMPACT trial

Researchers

Presenter

  • Dhvani Shah

Principal Investigators

  • Alan Martin

  • Robyn Kendall

  • Nancy Risebrough

  • Afisi Ismaila

Medical Centers

  • GlaxoSmithKline, Uxbridge, United Kingdom

  • GlaxoSmithKline plc, Collegeville, United States of America

  • ICON Health Economics, ICON plc, Vancouver, Canada

  • ICON Health Economics, ICON plc, Toronto, United States of America

  • ICON Health Economics, New York, United States of America

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Fluticasone furoate

  • Umeclidinium

  • Fluticasone

  • Azelastine/fluticasone propionate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved